- Home
- SRG vs UNCY Comparison
SRG vs UNCY Comparison
Compare SRG & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRG | UNCY |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.5M | 100.6M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SRG | UNCY |
|---|---|---|
| Price | $1.51 | $3.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $28.40 |
| AVG Volume (30 Days) | 139.9K | ★ 1.0M |
| Earning Date | 11-24-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.90 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,204,000.00 | $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10,044.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3.30 | N/A |
| 52 Week Low | $1.51 | $3.33 |
| 52 Week High | $4.16 | $8.74 |
Technical Indicators
Market Signals| Indicator | SRG | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 36.19 | 42.19 |
| Support Level | N/A | $3.34 |
| Resistance Level | $1.71 | $4.18 |
| Average True Range (ATR) | 0.09 | 0.21 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 1.56 | 40.00 |
Price Performance
Historical ComparisonAbout SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, sale, and leasing of diversified retail and mixed-use properties throughout the United States.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.